Eloxx doses first patients in Phase 2b EXACT trial of exaluren for nonsense mutation Alport syndrome
ELOX•Expected readouts
Topline results from the initial 16-week placebo-controlled portion are expected in mid-2027.
A final study readout is targeted for the end of 2027.
Trial dosing begins
Eloxx Pharmaceuticals began dosing patients in the Phase 2b EXACT trial of exaluren for nonsense mutation Alport syndrome.
The trial aims to evaluate whether exaluren can address the underlying genetic cause of the disease.
